In the last years, clinical trials testing ICI in advanced STS showed limited clinical activity in an unselected population of patients, with anecdotal durable responses to PD-1 blockade observed in undifferentiated pleomorphic STS and dedifferentiated liposarcoma. This evidence concerns the gene PDCD1 and telomere syndrome.